Alpha-MSH

Alpha-melanocyte-stimulating hormone (alpha-MSH) is an endogenous 13-amino acid neuropeptide derived from the precursor protein proopiomelanocortin (POMC). POMC is cleaved by prohormone convertases in the pituitary, skin, brain, and other tissues to produce a remarkable family of biologically active peptides including ACTH, beta-endorphin, and the three forms of MSH (alpha, beta, gamma). Alpha-MSH itself is cleaved from the N-terminal portion of ACTH and shares its first 13 amino acids.

The melanocortin system - comprising five G-protein-coupled receptors (MC1R through MC5R) and the two endogenous antagonists agouti protein and AgRP (agouti-related peptide) - is one of the most conserved and multifunctional signalling systems in vertebrate physiology. Alpha-MSH is the primary endogenous agonist for all five receptors, though with different affinities, which explains the extraordinary breadth of physiological processes it influences.

The best-understood function of alpha-MSH is regulation of pigmentation through MC1R on melanocytes. Alpha-MSH binding stimulates the production of eumelanin (dark pigmentation) over phaeomelanin (red/yellow pigmentation), determining hair and skin colour. Loss-of-function mutations in MC1R are associated with fair skin and red hair and dramatically increase melanoma risk - establishing alpha-MSH/MC1R signalling as a critical protection mechanism against UV-induced carcinogenesis.

The role of alpha-MSH in energy balance is mediated primarily through hypothalamic MC4R. In the arcuate nucleus of the hypothalamus, POMC-expressing neurons release alpha-MSH in response to satiety signals (particularly leptin and insulin), and this alpha-MSH acts on MC4Rs in the paraventricular nucleus to reduce food intake and increase energy expenditure. MC4R mutations are the most common monogenic cause of severe early-onset obesity in humans, occurring in approximately 2-5% of severely obese patients - making the melanocortin pathway one of the most compelling targets in obesity pharmacology.

The anti-inflammatory properties of alpha-MSH are mediated through multiple receptor subtypes and represent a substantial area of therapeutic research. Alpha-MSH potently inhibits the production of pro-inflammatory cytokines (IL-6, TNF-alpha, IL-1beta, IL-8) by macrophages, dendritic cells, and other immune cells. These effects are mediated primarily through MC1R and MC3R activation, downstream cAMP/PKA signalling, and inhibition of NF-kappaB transcription. In models of sepsis, colitis, brain ischemia, and arthritis, exogenous alpha-MSH significantly reduces tissue damage and inflammatory pathology.

The antipyretic effect of alpha-MSH is one of the most potent endogenous fever-reducing mechanisms known. Central administration of vanishingly small amounts of alpha-MSH (nanogram range) rapidly reduces fever through MC4R-mediated pathways distinct from COX/prostaglandin mechanisms. This makes alpha-MSH (and analogues) an attractive potential antipyretic for settings where conventional fever management is inadequate or contraindicated.

The central MC4R-mediated pro-sexual effects of alpha-MSH were the basis for the development of Melanotan II and its metabolite bremelanotide (PT-141), which became the first FDA-approved treatment for hypoactive sexual desire disorder in premenopausal women. The mechanism - activation of MC4Rs in the mesolimbic dopamine system and hypothalamic sexual behavior circuits - is entirely different from phosphodiesterase inhibitors like sildenafil and operates on desire/motivation rather than peripheral vascular tone.